QuANTUM wild-type Phase 3 trial for patients with FLT3-ITD-negative AML started

Acute myeloid leukemia (AML) is one of the most common forms of leukemia in adults. To date, there are no approved FLT3 inhibitors for patients with FLT3-ITD-negative AML, although sustained activation of the FLT3 receptor could also contribute to disease progression in this patient population.